LOS ANGELES (Reuters) - Biotechnology stocks have become somewhat of a safe haven as recession worries rattle the broader markets, but as the sector heads into one of its biggest earnings reporting weeks some companies still remain a bargain.John McCamant, editor of the Medical Technology Stock Letter, said the best bets are companies that turn out drugs for conditions “where you just can’t not spend money.”
